# Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT02225275** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Obinutuzumab

## Key facts

- **NCT ID:** NCT02225275
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-31
- **Primary completion:** 2021-05-19
- **Final completion:** 2021-05-19
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Due to slow accrual
- **Last updated:** 2022-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02225275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02225275, "Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02225275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*